George Shultz

George Shultz was not accused of participating in the Theranos fraud, but his role on the company’s board was nevertheless consequential. He was not the architect of the deception, nor its most visible enabler, yet he supplied something even more valuable than money or technical expertise: legitimacy. In a company built on confidence and secrecy, his name helped translate a shaky startup into something that could be mistaken for an institution. That mattered because Theranos was not sustained only by lies inside the company; it was sustained by the ability to make outsiders lower their guard.

Shultz brought to Theranos the kind of reputation that had been earned over decades in public life. He had served at the highest levels of government, and his career carried the aura of discipline, sobriety, and seriousness. People like Shultz often develop a professional identity built around judgment itself: the idea that they can detect competence, character, and danger through experience. That confidence can be useful in diplomacy, where ambiguity is the terrain. But it can become a liability in highly technical settings, where the surface signals of intelligence and polish are easy to mistake for real mastery.

His presence on the board reveals a deeper psychological pattern common among elites: the belief that association with excellence is itself a form of discernment. A seasoned statesman may assume he can recognize a serious founder the way he recognizes a serious ally or negotiator. Yet that instinct can fail when the subject is not statecraft but science. The Theranos scandal exposed that gap brutally. Prestige did not function as oversight; it functioned as insulation.

Shultz’s public persona was that of a sober institutionalist, someone associated with order, rules, and responsibility. The private consequence of that persona, however, was that it could be used as part of a trust machine. For investors, journalists, partners, and employees, his presence suggested that serious adults had already vetted the enterprise. That signal reduced skepticism. It did not prove fraud, but it helped create the social atmosphere in which fraud could continue.

There is no public record showing that Shultz intended to deceive anyone. The more troubling possibility is more ordinary: he likely believed he was dealing with a promising young founder and a disruptive technology that he did not fully understand. That is not exculpation; it is the anatomy of elite self-deception. People in his position often justify involvement by appealing to mentorship, national interest, or the hope of supporting innovation. Those motives can coexist with vanity, curiosity, and the desire to remain relevant. Being near power can be intoxicating, even for those who spent a lifetime wielding it.

The cost of that misjudgment was borne primarily by patients, employees, investors, and the public, all of whom were affected by the false credibility surrounding Theranos. But there was also a personal cost to Shultz’s legacy. His name, once associated with prudence and gravitas, became entangled with one of the most notorious corporate frauds of the century. He died in 2021 before the criminal case against Elizabeth Holmes concluded, leaving behind not a verdict, but a cautionary example: how a respected elder can become part of an illusion simply by trusting too easily in the appearance of seriousness.